{
Incyte Corporation

Companies

}
Symbol INCY
Name Incyte Corporation
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State DE
City Wilmington
Zipcode 19803
Website http://www.incyte.com
Track all markets on TradingView
Incyte Executive Sells Shares Amid Institutional Investor Activity and Analyst Ratings
Incyte Corporation's executive vice president sold 3,680 shares, reducing their ownership by 5.96%, now holding 58,042 shares valued at approximately $4.62 million. Institutional investors control 96.97% of the stock, with recent hedge fund activity indicating significant interest. UBS Group initiated coverage with a "neutral" rating and a $77 price target, suggesting an 11.30% upside.
MarketBeat
United States Dollar Incyte Corporation USA Vijay K Iyengar
Healthcare, Market Report
16:09 17.12.2024
insider sales and institutional investments shape incyte's stock performance
Incyte's executive vice president now holds 30,658 shares valued at approximately $2.31 million, reflecting a 16.47% decrease in ownership. Institutional investors control 96.97% of the stock, with recent hedge fund activity including significant increases in positions by Raymond James & Associates and New York State Teachers Retirement System. UBS Group initiated coverage with a "neutral" rating and a $77 price target, suggesting an 11.30% upside.
MarketBeat
United States Dollar Incyte Corporation USA Vijay K Iyengar Show more
Finance & Economy, Market Report
16:09 17.12.2024
Incyte Corporation Focuses on Cancer and Inflammatory Disease Therapeutics
Incyte Corporation focuses on developing therapeutic products for cancer and inflammatory diseases. Its revenue sources are primarily from product sales, accounting for 85.6%, followed by license income at 14.2%, and a minimal 0.2% from research and collaboration agreements.
MarketScreener
United States Dollar Incyte Corporation USA
Healthcare, Market Report
16:02 17.12.2024
Sun Pharma shares drop after US court blocks Leqselvi launch
Sun Pharma's shares fell over 5% to Rs 1,760.10 after a US Court issued a preliminary injunction blocking the launch of Leqselvi, a treatment for severe alopecia areata, until a favorable court decision or patent expiration. UBS noted that this does not eliminate future opportunities, while JPMorgan suggested the company might appeal or settle with Incyte, with a potential launch delayed until December 2026.
summary_large_image
United States Dollar SUN Pharmaceutical Industries Ltd. Incyte Corporation USA IND
TradFi, Market Report
08:40 04.11.2024
Evommune secures 115 million dollars to advance immune drug development
Evommune, a California biotech startup, has secured $115 million in Series C funding to advance its immune drug candidates, EVO756 and EVO301, targeting chronic immune conditions. The funding will support three Phase 2 trials, with results expected by the end of 2026. EVO756, an oral treatment for chronic skin hives, aims to be a first-in-class therapy, while EVO301 targets atopic dermatitis and shows promise in early testing.
BioPharma Dive
United States Dollar Regeneron Pharmaceuticals, Inc. Incyte Corporation Novartis AG Celldex Therapeutics, Inc. Sanofi USA Joe Biden Luis Pena Show more
Healthcare, News Article
16:05 31.10.2024
septerna raises 288 million in successful ipo targeting gpcr therapies
Septerna, a GPCR-focused biotech, raised $288 million in its IPO, pricing shares at $18 each, above the initial range. The company aims to advance its lead drug candidate, SEP-786, for hypoparathyroidism, with human testing underway and data expected in 2025. This marks a significant moment in a busy period for biotech IPOs, with Septerna being the 23rd this year.
BioPharma Dive
United States Dollar NASDAQ-100 Fund FUND Incyte Corporation Third Rock Ventures RA Capital Management LP Samsara Biocapital LP Septerna USA Jordan Saxe Donald Trump Jeff Finer Show more
Finance & Economy, Market Report
05:58 25.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Central Bank Actions Cryptocurrency Trends Market Sentiment Analysis Corporate Responsibility & ESG Banking Regulations Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Inflation Rates & CPI Data Cryptocurrency Regulations Mergers & Acquisitions Tokenomics and Crypto Economics Blockchain Technology Adoption Foreign Exchange Rates Market Analysis and Predictions Anti-Money Laundering (AML) Regulations Funding Rounds & Investments Hedge Funds & Private Equity SEC & Financial Compliance
Countries:
USA CHE JPN DEU CHN AUS IND GBR HKG KOR SGP TWN RUS THA FRA CAN ITA AUT BRA SAU
Companies:
Coinbase Global, Inc. Apple Inc. Ripples USD Solana USD Credit Suisse Real Estate Fund Siat BlackRock, Inc. NVIDIA Corporation Ethereum USD MicroStrategy Incorporated Tesla, Inc. Chainlink USD Volkswagen AG Bitwise Bitcoin ETF Nestlé S.A. Cardano USD MicroStrategy Inc Kraken Energy Corp. Hon Hai Precision Industry Co., Ltd. Google Inc. Amazon.com, Inc.
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Chinese Yuan British Pound Sterling South Korean Won Singapore Dollar Indian Rupee Malaysian Ringgit Canadian Dollar Colombian Peso Hong Kong Dollar Seychellois Rupee Philippine Peso Armenian Dram Russian Ruble
People:
Donald Trump Ali Martinez Jerome Powell Elon Musk Michael J. Saylor Paul Atkins David O. Sacks Charles Hoskinson Gary Gensler Joe Biden Patrick Hummel Sriram Krishnan Bo Hines Wiley Nickel Karin Keller-Sutter Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.